Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Debate erupts over 340B contract‑pharmacy restrictions and a clearinghouse alternative
Summary
Sponsors and safety‑net providers told the committee that manufacturer restrictions on contract pharmacies have reduced pharmacy access and 340B benefits for clinics and patients; manufacturers and trade groups warned the state should not limit audit or claims‑flagging tools used to detect duplicate discounts.
The House Committee on Behavioral Health and Health Care held extended testimony on legislation that would limit manufacturers’ ability to restrict which contract pharmacies covered 340B entities may use and would authorize a clearinghouse approach for verifying 340B claims rather than relying on a claims modifier.
Lede/nut: Sponsors described two complementary policy strands: HB 2,057 (technical change to authorize a neutral clearinghouse for transactional validation in commercial claims) and HB 2,385 (ban on manufacturer contract restrictions that narrow the pharmacies covered entities can designate). Supporters — FQHCs, hospital systems and pharmacy advocates — said pharmacy restrictions implemented in…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
